Park Avenue Institutional Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Park Avenue Institutional Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,548	Closed	-$133K	–	406
2016 Q2	$133K	Hold	1,548	–	–	0.11%	217
2016 Q1	$123K	Sell	1,548 -49	-3%	-$4.43K	0.11%	227
2015 Q4	$201K	Sell	1,597 -24	-1%	-$2.9K	0.17%	138
2015 Q3	$169K	Sell	1,621 -12	-0.7%	-$1.54K	0.15%	163
2015 Q2	$202K	Buy	+1,633	New	+$206K	0.16%	151

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Park Avenue Institutional Advisers's VRTX Position: Q3 2016 in Review

Park Avenue Institutional Advisers sold out of Vertex Pharmaceuticals (VRTX) in Q3 2016, closing a stake of 1,548 shares — an estimated $133K sold.

Park Avenue Institutional Advisers first reported a position in VRTX in Q2 2015 and held it in 5 quarters. The position peaked at $202K in Q2 2015. 491 funds tracked by Wall St. Rank hold VRTX as of Q3 2016.

Park Avenue Institutional Advisers reported no remaining Vertex Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Park Avenue Institutional Advisers sold 1,548 Vertex Pharmaceuticals shares in Q3 2016, an estimated $133K.
Park Avenue Institutional Advisers first reported a position in Vertex Pharmaceuticals in Q2 2015 and held it in 5 quarters.
Park Avenue Institutional Advisers's Vertex Pharmaceuticals position peaked at $202K in Q2 2015.
491 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2016.

Based on Park Avenue Institutional Advisers's 13F filing for Q3 2016, filed 15 Feb 2017.